Literature DB >> 33215039

Concurrent Prophylactic Mastectomy, Immediate Reconstruction, and Salpingo-Oophorectomy in High-Risk Patients: A Case Series.

Josephine A D'Abbondanza1, Ralph George2, Sari Kives3, Melinda A Musgrave1,4.   

Abstract

PURPOSE: There are limited data on coordinated breast and gynecological risk-reduction surgery for high-risk patients in Canada. Therefore, this study aims to evaluate the patient demographics, surgical details, and outcomes of prophylactic mastectomy (PM) with immediate reconstruction and bilateral salpingo-oophorectomy (BSO) in high-risk patients.
METHODS: We conducted a retrospective chart review at an academic center of patients who concurrently underwent PM with immediate reconstruction and laparoscopic BSO over a 7-year period (March 2010-February 2017) were identified.
RESULTS: A total of 16 patients underwent PM with immediate reconstruction and concurrent BSO. The mean age at the time of surgery was 46.2 ± 6.6 years. Thirteen (81%) patients were carriers of the BRCA1 or BRCA2 mutation. Two patients had prophylactic surgical therapy for BRCA1 mutation and 14 (87.5%) patients had prior oncological treatment. The most common type of procedures performed were skin-sparing, nipple-sparing mastectomy (56.2%) and reconstruction with acellular dermal matrix and implants (43.8%). All patients underwent laparoscopic BSO. The average combined case time was 282.5 ± 81.3 minutes with an average postoperative hospital stay of 1.3 ± 0.5 days. Six (37.5%) patients presented with 30-day postoperative complications, with higher rates in the alloplastic group. There were no gynecological complications.
CONCLUSIONS: In conclusion, our results demonstrate that a combined multidisciplinary surgical approach did not increase length of stay or 30-day complication rates. Furthermore, concurrent risk-reducing strategies are an effective option for patients at high risk of breast or ovarian cancer.
© 2020 The Author(s).

Entities:  

Keywords:  BRCA; breast cancer; breast reconstruction; risk-reduction surgery

Year:  2020        PMID: 33215039      PMCID: PMC7644831          DOI: 10.1177/2292550320928551

Source DB:  PubMed          Journal:  Plast Surg (Oakv)        ISSN: 2292-5503            Impact factor:   0.947


  26 in total

1.  Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.

Authors:  Sean C Dowdy; Michael Stefanek; Lynn C Hartmann
Journal:  Am J Obstet Gynecol       Date:  2004-10       Impact factor: 8.661

Review 2.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

Authors:  W Burke; M Daly; J Garber; J Botkin; M J Kahn; P Lynch; A McTiernan; K Offit; J Perlman; G Petersen; E Thomson; C Varricchio
Journal:  JAMA       Date:  1997-03-26       Impact factor: 56.272

3.  Access to breast reconstruction after mastectomy and patient perspectives on reconstruction decision making.

Authors:  Monica Morrow; Yun Li; Amy K Alderman; Reshma Jagsi; Ann S Hamilton; John J Graff; Sarah T Hawley; Steven J Katz
Journal:  JAMA Surg       Date:  2014-10       Impact factor: 14.766

4.  Breast reconstruction after mastectomy: A ten-year analysis of trends and immediate postoperative outcomes.

Authors:  Nicole Ilonzo; Ashley Tsang; Sara Tsantes; Alison Estabrook; Aye Moe Thu Ma
Journal:  Breast       Date:  2016-12-16       Impact factor: 4.380

5.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

6.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Outcomes and Cost Analysis in High-Risk Patients Undergoing Simultaneous Free Flap Breast Reconstruction and Gynecologic Procedures.

Authors:  Gabriel A Del Corral; Ari M Wes; John P Fischer; Joseph M Serletti; Liza C Wu
Journal:  Ann Plast Surg       Date:  2015-11       Impact factor: 1.539

Review 10.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.

Authors:  Nancie Petrucelli; Mary B Daly; Gerald L Feldman
Journal:  Genet Med       Date:  2010-05       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.